98%
921
2 minutes
20
Organoids are a cutting-edge technology in the life sciences field, with applications in precision medicine, bionic organs, and toxicological evaluations of chemicals. Their 3D structure closely resembles that of real organs, allowing more accurate functional mimicry. The 3D organoid culture system can simulate the growth state of cells in vivo and establish a suspension culture system for organoid 3D culture by using scaffold-less or scaffold technology to avoid direct contact between cells and plastic culture vessels. Furthermore, organoids can simulate the pathophysiological state of tissues and organs in vitro. This paper primarily discusses the construction methodologies, as well as the advantages and disadvantages of 3D culture systems for both scaffold-free organoids and scaffolded organoids. This review also summarizes the application of organoid models in chemical toxicology evaluation, drug screening and functional evaluation, establishment of in vitro disease models, and research on disease occurrence and potential mechanisms. The aim is to provide a reference for the research and practical applications of organoid-related scientific fields.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.biopha.2025.117942 | DOI Listing |
Sci Transl Med
September 2025
Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.
Oligodendrocytes, the myelinating cells of the central nervous system (CNS), are essential for the formation of myelin sheaths and pivotal for maintaining axonal integrity and conduction. Disruption of these cells and the myelin sheaths they produce is a hallmark of demyelinating conditions like multiple sclerosis or those resulting from certain drug side effects, leading to profound neurological impairments. In this study, we created a human brain organoid comprising neurons, astrocytes, and myelinating oligodendrocytes.
View Article and Find Full Text PDFMater Today Bio
October 2025
Leibniz Institute of Polymer Research Dresden, Division Polymer Biomaterials Science, Max Bergmann Center of Biomaterials Dresden, 01069, Dresden, Germany.
Glycosaminoglycan-based biohybrid hydrogels represent a powerful class of cell-instructive materials with proven potential in tissue engineering and regenerative medicine. Their biomedical functionality relies on a nanoscale polymer network that standard microscopy techniques cannot resolve. Here, we introduce an advanced analytical approach that integrates transmission electron microscopy, X-ray scattering, and computer simulations to directly and quantitatively characterize the nanoscale molecular network structure of these hydrogels.
View Article and Find Full Text PDFCancer Res
September 2025
Morgridge Institute for Research, Madison, Wisconsin, United States.
Patient-derived cancer organoids (PDCOs) are a valuable model to recapitulate human disease in culture with important implications for drug development. However, current methods for rapidly and reproducibly assessing PDCOs are limited. Label-free imaging methods are a promising tool to measure organoid level heterogeneity and rapidly screen drug response in PDCOs.
View Article and Find Full Text PDFiScience
September 2025
Biophysics Department, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Hessen, Germany.
Efforts to efficiently target brain tumors are constrained by the dearth of appropriate models to study tumor behavior toward treatment approaches as well as potential side effects to the surrounding normal tissue. We established a reproducible cerebral organoid model of brain tumorigenesis in an autologous setting by overexpressing , a common oncogene in brain tumors. GFP/c-MYC cells were isolated from tumor organoids and used in two different approaches: GFP/c-MYC cells co-cultured with cerebral organoid slices or fused as spheres to whole organoids.
View Article and Find Full Text PDFACS Biomater Sci Eng
September 2025
Chemical Engineering, University of Waterloo, Waterloo, Ontario N2L 3G1, Canada.
Patient-derived tumor organoids (PDTOs) are promising 3D disease models for developing personalized treatment methods. However, conventional technologies for making PDTOs have limitations such as batch-to-batch variation and low throughput. Droplet microfluidics (DM), which utilizes uniform droplets generated in microchannels, has demonstrated potential for creating organoids due to its high-throughput and controllable parameters.
View Article and Find Full Text PDF